LTPA2021506I1 - Anti-P-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui - Google Patents

Anti-P-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui

Info

Publication number
LTPA2021506I1
LTPA2021506I1 LTPA2021506C LTPA2021506C LTPA2021506I1 LT PA2021506 I1 LTPA2021506 I1 LT PA2021506I1 LT PA2021506 C LTPA2021506 C LT PA2021506C LT PA2021506 C LTPA2021506 C LT PA2021506C LT PA2021506 I1 LTPA2021506 I1 LT PA2021506I1
Authority
LT
Lithuania
Prior art keywords
treatment
inflammatory diseases
selectin antibodies
selectin
antibodies
Prior art date
Application number
LTPA2021506C
Other languages
English (en)
Original Assignee
Novartis Ag
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Oklahoma Medical Research Foundation filed Critical Novartis Ag
Publication of LTPA2021506I1 publication Critical patent/LTPA2021506I1/lt
Publication of LTC2662091I2 publication Critical patent/LTC2662091I2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTPA2021506C 2006-12-01 2021-04-13 Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui LTC2662091I2 (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87217006P 2006-12-01 2006-12-01
EP07867601A EP2097105A4 (en) 2006-12-01 2007-11-30 ANTI-P-SELECTINE ANTIBODIES AND METHODS FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES
PCT/US2007/024692 WO2008069999A2 (en) 2006-12-01 2007-11-30 Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases

Publications (2)

Publication Number Publication Date
LTPA2021506I1 true LTPA2021506I1 (lt) 2021-05-10
LTC2662091I2 LTC2662091I2 (lt) 2022-10-10

Family

ID=39492818

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP13164403.1T LT2662091T (lt) 2006-12-01 2007-11-30 Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui
LTPA2021506C LTC2662091I2 (lt) 2006-12-01 2021-04-13 Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP13164403.1T LT2662091T (lt) 2006-12-01 2007-11-30 Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui

Country Status (11)

Country Link
US (2) US8377440B2 (lt)
EP (3) EP3501538A1 (lt)
CY (1) CY1121072T1 (lt)
DK (1) DK2662091T3 (lt)
ES (1) ES2699273T3 (lt)
HU (3) HUE041957T2 (lt)
LT (2) LT2662091T (lt)
PL (1) PL2662091T3 (lt)
PT (1) PT2662091T (lt)
SI (1) SI2662091T1 (lt)
WO (1) WO2008069999A2 (lt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945565B2 (en) * 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
US20110212096A1 (en) 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
EP3501538A1 (en) 2006-12-01 2019-06-26 Novartis AG Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases
PL2654781T3 (pl) * 2010-12-21 2018-09-28 Novartis Ag Przeciwciała anty-p-selektynowe i sposoby ich zastosowania i identyfikacji
US10307487B2 (en) 2013-07-09 2019-06-04 President And Fellows Of Harvard College Microvessel endothelial cell surface markers and uses thereof
US10206941B2 (en) 2013-07-09 2019-02-19 President And Fellows Of Harvard College Venule endothelial cell genes and uses thereof
JOP20190101A1 (ar) * 2016-11-03 2019-05-05 Novartis Ag أنظمة علاج
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
EP3595645A1 (en) 2017-03-15 2020-01-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for the treatment of thrombosis in patients suffering from a myeloproliferative neoplasm
BR112019023540A2 (pt) * 2017-05-10 2020-05-26 The Wistar Institute Of Anatomy And Biology Método para gerar uma sequência de ácidos nucleicos e para tratar um sujeito, anticorpo codificado por dna estruturalmente modificado, e, composição.
WO2018234308A1 (en) 2017-06-20 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS FOR IDENTIFYING IF PATIENTS WITH ACUTE CARDIAC DISEASE FAILURE (ICAD) HAVE A HYPERCOAGULABLE CONDITION
CN107299112A (zh) * 2017-06-22 2017-10-27 广东药科大学 一种炎症分子（psgl‑1）缺失的脂代谢异常模型的构建及其应用
WO2019025847A1 (en) 2017-08-04 2019-02-07 Novartis Ag TREATMENT DIAGRAMS
US20210002374A1 (en) 2018-03-08 2021-01-07 Novartis Ag USE OF an anti-P-selectin antibody
AU2020289364A1 (en) 2019-06-07 2022-01-06 Novartis Ag Use of an anti-P-selectin antibody
EP3790545A4 (en) 2019-07-17 2021-07-28 Emmaus Medical, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF SICKLE CLEANEMIA AND THALASSEMIA
BR112022008097A2 (pt) 2019-10-30 2022-08-02 Novartis Ag Formulação de anticorpo que contém crizanlizumabe
US20230020548A1 (en) 2019-12-09 2023-01-19 Novartis Ag Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
CN115176005A (zh) 2019-12-18 2022-10-11 诺华股份有限公司 用于治疗血红蛋白病的组合物和方法
WO2022269518A2 (en) 2021-06-23 2022-12-29 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) * 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4783399A (en) 1984-05-04 1988-11-08 Scripps Clinic And Research Foundation Diagnostic system for the detection of cytomegalovirus
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
ATE169227T1 (de) 1991-09-30 1998-08-15 Biogen Inc Hemmung von gefässverengung unter verwendung von anti-padgem antikörpern.
WO1993022436A1 (en) 1992-04-30 1993-11-11 Genentech, Inc. Lectin domain variants of selectin
JP3720352B2 (ja) * 1992-05-05 2005-11-24 アエレス バイオメディカル リミティド Ｐ−セレクチンに対する抗体及びその利用
US6033667A (en) 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
WO1994025067A1 (en) 1993-05-04 1994-11-10 Cytel Corporation Antibodies to p-selectin and their uses
US5914110A (en) 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
EP0759781B1 (en) * 1994-06-03 2006-01-25 The CBR Institute for Biomedical Research, Inc. Compositions for treating and preventing atherosclerosis
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
GB9612629D0 (en) 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
AU752730B2 (en) 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
US7067313B1 (en) 1999-07-14 2006-06-27 D. Collen Research Foundation Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
DE60118362T2 (de) 2000-05-19 2007-05-24 The Center for Blood Research, Inc., Boston VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US20030198639A1 (en) 2002-04-16 2003-10-23 Frenette Paul S. Methods of treating sickle cell disease
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
EP1542704A1 (en) * 2002-04-18 2005-06-22 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
DK1572744T3 (da) * 2002-12-16 2010-09-20 Genentech Inc Immunoglobulinvarianter og deres anvendelser
EP2357201B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
EP3501538A1 (en) 2006-12-01 2019-06-26 Novartis AG Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases
US20110212096A1 (en) 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
US8945565B2 (en) 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
EP3388527A1 (en) 2008-05-15 2018-10-17 Tetherex Pharmaceuticals Corporation Anti-psgl-1 antibodies and methods of identification and use
PL2654781T3 (pl) 2010-12-21 2018-09-28 Novartis Ag Przeciwciała anty-p-selektynowe i sposoby ich zastosowania i identyfikacji

Also Published As

Publication number Publication date
EP2662091A2 (en) 2013-11-13
HUE041957T2 (hu) 2019-06-28
ES2699273T3 (es) 2019-02-08
SI2662091T1 (sl) 2019-01-31
PL2662091T3 (pl) 2019-05-31
HUS2100011I1 (hu) 2021-05-28
EP2662091B1 (en) 2018-08-22
US8377440B2 (en) 2013-02-19
CY1121072T1 (el) 2019-12-11
LTC2662091I2 (lt) 2022-10-10
US20140072551A1 (en) 2014-03-13
US20110243926A1 (en) 2011-10-06
DK2662091T3 (en) 2018-12-17
HUS2100015I1 (hu) 2021-05-28
EP2097105A2 (en) 2009-09-09
EP2097105A4 (en) 2010-09-15
LT2662091T (lt) 2018-12-10
WO2008069999A3 (en) 2008-12-04
US9556266B2 (en) 2017-01-31
PT2662091T (pt) 2018-12-03
WO2008069999A2 (en) 2008-06-12
EP3501538A1 (en) 2019-06-26
EP2662091A3 (en) 2014-03-12

Similar Documents

Publication Publication Date Title
LTPA2021506I1 (lt) Anti-P-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui
LTPA2020523I1 (lt) Anti-CD79b antikūnai ir imunokonjugatai ir jų panaudojimo būdai
LTPA2020540I1 (lt) Antikūnai Xa veiksnio inhibitoriams ir jų naudojimo būdai
ATE538137T1 (de) Antikörper gegen menschliches il-22 und verwendungen davon
HK1223114A1 (zh) 抗因子 單克隆抗體及其使用方法
LTPA2016005I1 (lt) Anti-il-5 antikūnų skyrimo būdai
DK2222706T3 (da) Antibodies against human nkg2d and uses thereof
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
IL200572A0 (en) Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
IL199045A0 (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
HK1171458A1 (en) Antibodies against human il 17 and uses thereof il17
EP2170950A4 (en) ANTI-IL-20 ANTIBODIES AND ITS USE IN THE TREATMENT OF INFLAMMATORY DISEASES ASSOCIATED WITH IL-20
DK2056807T3 (da) Behandling af inflammatoriske sygdomme
DK2480574T3 (da) Anti-cd33-antistoffer og deres anvendelse til immunotargeting i behandlingen af cd33-associerede sygdomme
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
ZA200902419B (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
LTPA2018508I1 (lt) Anti-FGF23 antikūnas ir jį apimanti farmacinė kompozicija
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
EP2021016A4 (en) CXCL13 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY DISEASES
IL201034A0 (en) Novel human anti-r7v antibodies and uses thereof
BR112013018454A2 (pt) "anticorpo anti-p-selectina e seu uso no tratamento ou inibição de doenças trombóticas e inflamatórias, bem como composição que o compreende"
DK2328553T3 (da) Corticosteroider til behandling af inflammatoriske sygdomme i mave-tarm-kanalen
BRPI0811572A2 (pt) Uso de compostos imunomoduladores no tratamento de doenças alérgicas
ZA200904382B (en) Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-retaled diseases
HK1144247A1 (en) Use of osteoblasts in the treatment of inflammatory rheumatic diseases